Health Technology
Takeda Pharmaceutical Co., Ltd.
In the news
- From Avigan to remdesivir, hopes run high for coronavirus drugs Mar 31, 2020
- Johnson & Johnson seeks coronavirus vaccine by early 2021 Mar 31, 2020
- Japan's Takeda in push to debut COVID-19 treatment this year Mar 20, 2020
- Silver linings emerge from the coronavirus gloom Mar 11, 2020
- Office furniture makers' new frontier: the home Mar 1, 2020 See more articles on Takeda Pharmaceutical Co., Ltd.
Business Summary
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Financial Highlights
| Mar 2019 | JPY | USD |
| Revenue | 2,097.22B | 18,911.85M |
| Gross Profit | 1,242.84B | 11,207.41M |
| Operating income | 181,857M | 1,639.90M |
| Income before tax | 94,896M | 855.73M |
| Net income | 109,126M | 984.05M |
| EBITDA | 454,303M | 4,096.70M |
| Diluted EPS | 112.86 | 1.01 |
| Dividends Per Share | 180 | 1.62 |
| Total Assets | 13,872.32B | 125,331.55M |
| Total liabilities | 8,708.73B | 78,680.35M |
| Total equity | 5,159.58B | 46,615.00M |
| Operating cash flow | 302,609M | 2,728.79M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 1,777.82B | 1,807.37B | 1,732.05B | 1,770.53B | 2,097.22B |
| Gross Profit | 1,134.39B | 1,161.84B | 1,017.65B | 1,148.86B | 1,242.84B |
| Operating income | 195,804M | 175,770M | 86,972M | 195,320M | 181,857M |
| Income before tax | -145,437M | 120,539M | 143,346M | 217,205M | 94,896M |
| Net income | -145,775M | 80,166M | 114,940M | 186,886M | 109,126M |
| EBITDA | 387,391M | 353,275M | 258,398M | 377,447M | 454,303M |
| Diluted EPS | -185.37 | 101.71 | 146.25 | 237.55 | 112.86 |
| Dividends Per Share | 180 | 180 | 180 | 180 | 180 |
| Total Assets | 4,296.19B | 3,824.08B | 4,346.79B | 4,106.46B | 13,872.32B |
| Total liabilities | 2,090.01B | 1,812.88B | 2,397.82B | 2,089.05B | 8,708.73B |
| Total equity | 2,137.04B | 1,948.69B | 1,894.26B | 1,997.42B | 5,159.58B |
| Operating cash flow | 183,441M | 26,552M | 260,067M | 379,600M | 302,609M |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 16,183.14M | 15,050.91M | 15,994.93M | 15,974.84M | 18,911.85M |
| Gross Profit | 10,326.11M | 9,675.22M | 9,397.74M | 10,365.80M | 11,207.41M |
| Operating income | 1,782.36M | 1,463.72M | 803.15M | 1,762.30M | 1,639.90M |
| Income before tax | -1,323.88M | 1,003.78M | 1,323.75M | 1,959.76M | 855.73M |
| Net income | -1,326.95M | 667.58M | 1,061.43M | 1,686.20M | 984.05M |
| EBITDA | 3,526.33M | 2,941.89M | 2,386.22M | 3,405.56M | 4,096.70M |
| Diluted EPS | -1.68 | 0.84 | 1.35 | 2.14 | 1.01 |
| Dividends Per Share | 1.63 | 1.49 | 1.66 | 1.62 | 1.62 |
| Total Assets | 35,823.98M | 34,023.62M | 39,009.18M | 38,612.71M | 125,331.55M |
| Total liabilities | 17,427.69M | 16,129.56M | 21,518.70M | 19,643.19M | 78,680.35M |
| Total equity | 17,819.86M | 17,337.88M | 16,999.56M | 18,781.60M | 46,615.00M |
| Operating cash flow | 1,669.82M | 221.11M | 2,401.63M | 3,424.99M | 2,728.79M |
Valuation Measures
| Mar 2019 | |
| PER | 39.83 |
| ROA | 1.21% |
| ROE | 3.04% |
| Operating margin | 8.67% |
| Profit margin | 5.20% |
Key executives
- President, CEO & Representative Director: Christophe Weber
- Chief Financial Officer & Director: Constantine Saroukos
- Director, Research & Development President: Andrew S. Plump
- Chief Ethics & Compliance Officer: Mwana Lugogo
- Executive Officer & Global General Counsel: Yoshihiro Nakagawa
Shareholders
- Nomura Asset Management Co., Ltd. (3.4%)
- Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.3%)
- BlackRock Fund Advisors (3.1%)
- Nippon Life Insurance Co. (2.2%)
- The Vanguard Group, Inc. (1.9%)
- Nikko Asset Management Co., Ltd. (1.5%)
- Capital Research & Management Co. (World Investors) (1.5%)
- State Street Global Advisors Ltd. (1.5%)
- Mondrian Investment Partners Ltd. (1.3%)
- Wellington Management Co. LLP (1.2%)
Contact Details
- Website:http://www.takeda.co.jp
- Address: 4-1-1 Dosho-machi, Chuo-Ku, Osaka, 540-8645, Japan
- Phone: +81.6.6204.2111
Related Companies
- Takeda Pharmaceutical Co. Ltd. /Non Core Latin America Assets/
- Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
- Takeda Re Insurance AG
- Takeda Pharmaceutical Co. Ltd. /Tachosil Business/
- Plasmapunkt Favoriten GmbH
- Takeda Malaysia Sdn. Bhd.
- Takeda Pharmaceutical Co. Ltd. /Latam Bus/
- Takeda Oranienburg Real Estate GmbH & Co. KG
- Takeda Consumer Healthcare Co. Ltd.
- Pvp Biologics, Inc.
- Takeda Pharmaceutical Director Incentive Plan
- Takeda Pharmaceutical Employee Incentive Plan
- Oy Leiras Takeda Pharmaceuticals AB
- Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
- Takeda Pharma AB
- Takeda Development Center Americas, Inc.
- Takeda Ukraine LLC
- Takeda Pharmaceuticals Taiwan Ltd.
- Takeda SRL
- Takeda Hellas SA
- Takeda Christiaens SCA/CVA
- Takeda Belgium SCA/CVA
- Takeda Vaccines Pte Ltd.
- Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
- Takeda Development Center Asia Pte Ltd.
- Takeda Pharma Sp zoo
- Takeda Mexico SA de CV
- Takeda Kazakhstan LLP
- Takeda Pharmaceuticals Korea Co., Ltd.
- Takeda Farmaceutica Espana SA
Competitors
- Sanofi
- AstraZeneca PLC
- Grifols, S.A. Class A
- Amgen Inc.
- Roche Holding AG
- Amicus Therapeutics, Inc.
- Protalix Biotherapeutics, Inc.
- Novartis AG
- Pfizer Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- AbbVie, Inc.
- CSL Limited
- Bristol-Myers Squibb Company
- Allergan plc
- Bayer AG
- Biotest AG Pref
- UCB S.A.
- Merck KGaA
- Swedish Orphan Biovitrum AB
- Novo Nordisk A/S Class B
- ISU Abxis Co., Ltd.
- Emmaus Life Sciences, Inc.
- Dr. Reddy's Laboratories Ltd.
- Hypera S.A.
- Green Cross Corporation
- MorphoSys AG
- Ipsen SA
- Faes Farma, S.A.
- Daewoong Co., Ltd.
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 3 Apr, 2020